Exclusive Online Content
Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced a collaboration agreement to innovate novel medicines they believe will significantly change….
Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect
Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….
Radiant Biotherapeutics Emerges From Stealth Mode With $8-Million Seed Round & Two Pharma Partnerships
Radiant Biotherapeutics emerged from stealth mode unveiling an $8-million seed financing and two significant pharmaceutical partnerships. The company, based on foundational IP from….
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia
NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….
Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences
Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….
Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….
Roquette Cuts Ribbon on $25-Million Pharmaceutical Innovation Center in the US
Roquette recently celebrated the grand opening of its new Pharmaceutical Innovation Center, located near Philadelphia, PA, right in the heart of the United States’ Northeastern pharmaceutical corridor…..
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne & San Diego
New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages….
EXCLUSIVE ONLINE CONTENT
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….